Pfizer's Viagra Patent Should Stand Firm: China Court

Law360, New York (June 5, 2006, 12:00 AM EDT) -- In a move that may thwart Chinese knock-offs of the popular anti-erectile dysfunction drug Viagra, a Beijing court has ruled that China’s patent review board erred when it invalidated Pfizer Inc.’s patent, marking the latest turn in the country’s attempts to quell pharmaceutical piracy.

The news comes two years after the New York-based pharmaceutical giant appealed a decision by China's State Intellectual Property Office.

That ruling overturned Pfizer's patent on sildenafil citrate, the main ingredient in Viagra, giving Chinese drug companies the right to copy the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.